Abatacept treatment in pSS patients reduces circulating numbers of ICOS+ cTfh cells resulting in an attenuated Tfh cell-dependent B cell hyperactivity (235) providing a promising therapy for pSS and some other autoimmune pathologies. This evidence concerns the gene ICOS and peeling skin syndrome.